The stock of Flex Pharma Inc (NASDAQ:FLKS) is a huge mover today! About 100,325 shares traded hands or 5.55% up from the average. Flex Pharma Inc (NASDAQ:FLKS) has declined 52.69% since April 5, 2016 and is downtrending. It has underperformed by 54.64% the S&P500.
The move comes after 7 months positive chart setup for the $114.91 million company. It was reported on Nov, 7 by Barchart.com. We have $12.08 PT which if reached, will make NASDAQ:FLKS worth $111.46M more.
Flex Pharma Inc (NASDAQ:FLKS) Ratings Coverage
Out of 2 analysts covering Flex Pharma (NASDAQ:FLKS), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Flex Pharma has been the topic of 3 analyst reports since August 21, 2015 according to StockzIntelligence Inc. On Friday, October 14 the stock rating was downgraded by Cantor Fitzgerald to “Hold”. The firm has “Hold” rating given on Friday, August 21 by Zacks. The company was upgraded on Wednesday, September 2 by Zacks.
According to Zacks Investment Research, “Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts.”
More news for Flex Pharma Inc (NASDAQ:FLKS) were recently published by: Marketwatch.com, which released: “Virtual Stock Exchange” on January 28, 2015. Businesswire.com‘s article titled: “Flex Pharma Announces FLX-787 as Clinical Drug Candidate” and published on November 10, 2015 is yet another important article.
FLKS Company Profile
Flex Pharma, Inc., incorporated on February 26, 2014, is a biotechnology firm that is developing treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Firm operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s product candidates are based on the mechanism of action described as Chemical Neuro Stimulation, which is the process by which a small molecule chemical signal, acting topically, is translated into a neuronal sensory signal that produces a beneficial effect. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing products using TRP activators.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.